文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

立体定向脑池灌洗联合尿激酶与尼莫地平预防动脉瘤性蛛网膜下腔出血继发性脑损伤(SPLASH):随机对照试验研究方案

Stereotactic cisternal lavage in patients with aneurysmal subarachnoid hemorrhage with urokinase and nimodipine for the prevention of secondary brain injury (SPLASH): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2021-04-15

BACKGROUND: Delayed cerebral infarction (DCI) is a major cause of death and poor neurological outcome in patients with aneurysmal subarachnoid hemorrhage (aSAH). Direct intrathecal therapies with fibrinolytic and spasmolytic drugs have appeared promising in clinical trials.…

要点

  • SPLASH试验评估经立体定向脑室脑池造瘘导管行脑池灌洗尿激酶、尼莫地平与林格液的安全性及神经功能结局。
  • 主要终点为aSAH后6个月改良Rankin量表0-3分的受试者比例。

核心结论

  • 该研究方案旨在评估经立体定向导管脑池灌洗尿激酶、尼莫地平与林格液治疗aSAH的安全性和改善神经功能结局的疗效。

研究设计与样本

  • 患者按1:1随机分配至仅标准治疗组或标准治疗联合研究性治疗组。

关键数值与推荐

  • 主要终点为aSAH后6个月改良Rankin量表评分0-3分的受试者比例。
  • 研究性治疗为经立体定向植入基底池的导管给予尿激酶、尼莫地平与林格液行脑池灌洗。
  • 次要终点包括其他临床和替代结局参数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Delayed cerebral infarction (DCI) is a major cause of death and poor neurological outcome in patients with aneurysmal subarachnoid hemorrhage (aSAH). Direct intrathecal therapies with fibrinolytic and spasmolytic drugs have appeared promising in clinical trials. However, access to the subarachnoid space for intrathecal drug administration is an unsolved problem so far, especially in patients with endovascular aneurysm securing. We investigate a therapy protocol based on stereotactic catheter ventriculocisternostomy (STX-VCS), a new approach to overcome this problem. The primary objective of this study is to assess whether cisternal lavage with urokinase, nimodipine, and Ringer's solution administered via a stereotactically implanted catheter into the basal cisterns (= investigational treatment (IT)) is safe and improves neurological outcome in patients with aSAH. METHODS: This is a randomized, controlled, parallel-group, open-label phase II trial. Fifty-four patients with severe aSAH (WFNS grade ≥ 3) will be enrolled at one academic tertiary care center in Southern Germany. Patients will be randomized at a ratio of 1:1 to receive either standard of care only or standard of care plus the IT. The primary endpoint is the proportion of subjects with a favorable outcome on the Modified Rankin Scale (defined as mRS 0-3) at 6 months after aSAH. Further clinical and surrogate outcome parameters are defined as secondary endpoints. DISCUSSION: New approaches for the prevention and therapy of secondary brain injury in patients with aSAH are urgently needed. We propose this RCT to assess the clinical safety and efficacy of a novel therapy protocol for intrathecal administration of urokinase, nimodipine, and Ringer's solution. TRIAL REGISTRATION: Deutsches Register Klinischer Studien (German Clinical Trials Register), DRKS00015645 . Registered on 8 May 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Roelz R, Schubach F, Coenen VA, et al. Stereotactic cisternal lavage in patients with aneurysmal subarachnoid hemorrhage with urokinase and nimodipine for the prevention of secondary brain injury (SPLASH): study protocol for a randomized controlled trial. Trials. 2021. PMID: 33858493. doi:10.1186/s13063-021-05208-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。